Among the available new treatment modalities for long-term prophylaxis, plasma-derived C1-esterase inhibitor (pdC1-INH) concentrates represent an alternative treatment for prevention of HAE attacks. This evidence concerns the gene SERPING1 and hereditary angioedema.